Consensus Bio-Rad Laboratories, Inc. NYSE

Stocks

BIO.B

US0905721082

Medical Equipment, Supplies & Distribution

Market Closed - NYSE 16:10:00 2026-10-27 EDT			5-day change	1st Jan Change
379.50 ^USD	+4.22%		-.--%	+22.14%

11-05	RBC Raises Price Target on Bio-Rad Laboratories to $440 From $390, Keeps Outperform Rating	MT
11-04	Bio-Rad Laboratories Q3 Adjusted Earnings, Revenue Rise	MT

1cff56d846ab8b9487d5dd31.1-2N1yo1_IKnQAuHApNP4lw4KKFd1iqxREqZxjCIZbE.-t-5gVNUzLTTLE3rS_03pmVScNkN4HKANSLhtGjNAcCyptjibEKz0J4DZA~e1362f97c77e75a4348144c74c77042d

Analysts' recommendations: Bio-Rad Laboratories, Inc.

11-05	RBC Raises Price Target on Bio-Rad Laboratories to $440 From $390, Keeps Outperform Rating	MT
08-07	RBC Adjusts PT on Bio-Rad Laboratories to $390 From $370, Maintains Outperform Rating	MT
08-05	RBC Adjusts Price Target on Bio-Rad Laboratories to $370 From $320, Maintains Outperform Rating	MT
05-15	Bio-Rad Laboratories' Sales Growth Set to Recover in 2027, RBC Says	MT
04-07	Citigroup Downgrades Bio-Rad Laboratories to Neutral From Buy, Adjusts Price Target to $300 From $375	MT
02-13	UBS Adjusts Price Target on Bio-Rad Laboratories to $335 From $350, Maintains Buy Rating	MT
25-10-30	Analyst recommendations: Boeing, Alphabet, Caterpillar, Chipotle, Wayfair…
25-09-03	RBC Raises Price Target on Bio-Rad Laboratories to $437 From $409, Keeps Outperform Rating	MT
25-08-01	UBS Adjusts Price Target on Bio-Rad Laboratories to $325 From $310, Maintains Buy Rating	MT
25-08-01	RBC Raises Price Target on Bio-Rad Laboratories to $409 From $387, Keeps Outperform Rating	MT
25-07-01	RBC Raises Price Target on Bio-Rad Laboratories to $387 From $381, Keeps Outperform Rating	MT
25-05-02	UBS Adjusts Price Target on Bio-Rad Laboratories to $310 From $355, Maintains Buy Rating	MT
25-05-02	RBC Cuts Price Target on Bio-Rad Laboratories to $392 From $409, Keeps Outperform Rating	MT
25-04-08	RBC Cuts Price Target on Bio-Rad Laboratories to $409 From $430, Keeps Outperform Rating	MT
25-02-14	UBS Adjusts Price Target on Bio-Rad Laboratories to $355 From $390, Keeps Buy Rating	MT
25-02-14	RBC Cuts Price Target on Bio-Rad Laboratories to $447 From $477, Keeps Outperform Rating	MT
25-02-04	RBC Trims Price Target on Bio-Rad Laboratories to $477 From $481, Keeps Outperform Rating	MT
24-12-09	RBC Raises Price Target on Bio-Rad Laboratories to $481 From $469, Keeps Outperform Rating	MT
24-10-31	UBS Adjusts Price Target on Bio-Rad Laboratories to $390 From $400, Maintains Buy Rating	MT
24-10-01	Citigroup Upgrades Bio-Rad Laboratories to Buy From Neutral, Adjusts Price Target to $400 From $350	MT
24-09-13	RBC Raises Price Target on Bio-Rad Laboratories to $446 From $401, Keeps Outperform Rating	MT
24-08-28	Wells Fargo Initiates Bio-Rad Laboratories at Equalweight With $340 Price Target	MT
24-08-02	Citigroup Adjusts Price Target on Bio-Rad Laboratories to $350 From $300	MT
24-08-02	UBS Adjusts Price Target on Bio-Rad Laboratories to $400 From $385, Maintains Buy Rating	MT
24-08-02	RBC Trims Price Target on Bio-Rad Laboratories to $401 From $402, Keeps Outperform Rating	MT

More recommendations

Other Medical Equipment, Supplies & Distribution

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ABBOTT LABORATORIES					+7.82%
	MEDTRONIC PLC					+2.77%
	STRYKER CORPORATION					+4.48%
	ESSILORLUXOTTICA					+11.41%
	CENCORA, INC.					+11.8%
	BECTON, DICKINSON AND COMPANY					-7.7%
	IDEXX LABORATORIES, INC.					+6.08%
	HOYA CORPORATION					+36.89%
	ALCON INC.					+20.39%
	Average					+10.44%
	Weighted average by Cap.					+8.32%